TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

Agents Chemother 2005;49:1337-9.
5A.66 Krueger WA et al. Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem
administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob
Agents Chemother 2005;49:1881-9.
5A.67 Kuti JL et al. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy
for meropenem. J Clin Pharmacol 2003;43:1116-23.
5A.68 Sendzik J et al. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical
data. Int J Antimicrob Agents 2009;33:194-200.
5A.69 American Academy of Pediatrics Committee on Infectious Diseases. The use of systemic fluoroquinolones.
Pediatrics 2006;118:1287-92.
5A.70 Velissariou IM. The use of fluoroquinolones in children: recent advances. Expert Rev Anti Infect
Ther 2006;4:853-60.
5A.71 Schaad UB. Fluoroquinolone antibiotics in infants and children. Infect Dis Clin North Am 2005;19:
617-28.
5A.72 Schaad UB. Will fluoroquinolones ever be recommended for common infections in children? Pediatr
Infect Dis J 2007;26:865-7.
5A.73 Dagan R et al. Potential role of fluoroquinolone therapy in childhood otitis media. Pediatr Infect Dis J
2004;23:390-8.
5A.74 Gendrel D et al. Fluoroquinolones in paediatrics: a risk for the patient or for the community? Lancet
Infect Dis 2003;3:537-46.
5A.75 Zacher JL et al. False positive urine opiate screening associated with fluoroquinolone use. Ann Pharmacother
2004;38:1525-8.
5A.76 Baden LR et al. Quinolones and false positive urine screening for opiates by immunoassay technology.
J Am Med Assoc 2001;286:3115-9.
5A.77 Rubinstein E et al. Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother 2002;49:593-6.
5A.78 Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin,
gatifloxacin and moxifloxacin. Pharmacotherapy 2001;12:1468-72.
5A.79 Owens RC et al. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect
Dis 2006;43:1603-11.
5A.80 van der Linden PD et al. Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous
reports in the period 1988 to 1998. Arthritis Care Res 2001;45:235-9.
5A.81 van der Linden PD et al. Increased risk of Achilles tendon rupture with quinolone antibacterial use,
especially in elderly patients taking oral corticosteroids. Arch Intern Med 2003;163:1801-7.
5A.82 Khaliq Y et al. Fluoroquinolone associated tendinopathy: a critical review of the literature. Clin Infect
Dis 2003;36:1404-10.
5A.83 Van Bambeke F et al. Quinolones in 2005: an update. Clin Microbiol Infect 2005;11:256-80.
5A.84 Sode J et al. Use of fluoroquinolone and risk of Achilles tendon rupture: a population-based cohort
study. Eur J Clin Pharmacol 2007;63:499-503.
5A.85 Chhajed PN et al. Achilles tendon disease in lung transplant recipients: association with ciprofloxacin.
Eur Respir J 2002;19:469-71.
5A.86 Fish DN. Levofloxacin: update and perspectives on one of the original ―respiratory quinolones‖. Expert
Rev Anti Infect Ther 2003;1:371-87.
5A.87 Kelesidis T et al. Levofloxacin-induced hypoglycemia: a rare but life-threatening side effect of a widely
used antibiotic. Am J Med 2009;122:e3-4.
5A.88 Kelesidis T et al. Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side
effect. Am J Med 2010;123:e5-6.
5A.89 Aspinall SL et al. Severe dysglycemia with the fluoroquinolones: a class effect? Clin Infect Dis 2009;
49:402-8.
5A.90 Sode J et al. Use of fluoroquinolone and risk of Achilles tendon rupture: a population-based cohort
study. Eur J Clin Pharmacol 2007;63:499-503.
5A.91 Caeiro JP et al. Moxifloxacin: a novel fluoroquinolone with a broad spectrum of activity. Expert Rev
Anti Infect Ther 2003;1:363-70.
5A.92 Burkhardt O et al. 10 years‘ experience with the pneumococcal quinolone moxifloxacin. Expert Rev
Anti Infect Ther 2009;7:645-68.
5A.93 Sode J et al. Use of fluoroquinolone and risk of Achilles tendon rupture: a population-based cohort
study. Eur J Clin Pharmacol 2007;63:499-503.
5A.94 Rybak MJ et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from
the Infectious Diseases Society of America, the American Society of Health-System Pharmacists and
the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49:325-7.
5A.95 Giuliano C et al. Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of
MRSA infections. Expert Rev Anti Infect Ther 2010;8:95-106.
5A.96 Thomson AH et al. Development and evaluation of vancomycin dosage guidelines designed to achieve
new target concentrations. J Antimicrob Chemother 2009;63:1050-7.
5A.97 Frymoyer A et al. Current recommended dosing of vancomycin for children with invasive methicillinresistant
Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J 2008;28:398-402.
5A.98 Chua K et al. Treating Gram-positive infections: vancomycin update and the whys, wherefores and
evidence base for continuous infusion of anti-Gram-positive antibiotics. Curr Opin Infect Dis 2009;
22:525-34.
5A.99 Boffi el Amari E et al. High versus standard dose vancomycin for osteomyelitis. Scand J Infect Dis
2004;36:712-7.
5A.100 Wang JT et al. Necessity of a loading dose when using vancomycin in critically ill patients. J Antimicrob
Chemother 2001;47:246.
5A.101 Dehority W. Use of vancomycin in pediatrics. Pediatr Infect Dis J 2010;29:462-4.
5A.102 Hazlewood KA et al. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?
Am J Med 2010;123:182.e1-7.
5A.103 Lodise TP et al. Larger vancomycin doses (at least four grams per day) are associated with an increased
incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;52:1330-6.
5A.104 Lodise TP et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity